Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Vascular Cancer|Hypothalamic Cancer|Hypothalamic Diseases|Hypogonadism|Prostatic Hyperplasia|Prostate Cancer|Testicular Cancer|Skin Diseases, Vascular|Bladder Cancer|Inflammation|Protein Deficiency|Deficiency Diseases|Anal Gland Cancer|Skin Cancer|Pituitary Cancer|Prostatic Diseases|Testicular Diseases|Pituitary Diseases|Hypopituitarism|Pregnancy Outcomes|Bone Cancer
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
|
| [18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Prostate Cancer|Bone Cancer |
2016-02-11 |
|
| IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |
|
| DHT-3 | P2 |
Completed |
Prostate Cancer|Pituitary Diseases|Testicular Diseases|Hypothalamic Cancer|Hypopituitarism|Skin Diseases, Vascular|Hypothalamic Diseases|Prostatic Hyperplasia|Vascular Cancer|Pregnancy Outcomes|Pituitary Cancer|Testicular Cancer|Anal Gland Cancer|Bladder Cancer|Deficiency Diseases|Prostatic Diseases|Protein Deficiency|Skin Cancer|Inflammation|Hypogonadism |
2009-01-01 |